Broadwood Capital Inc

Major 10% shareholder BROADWOOD PARTNERS buys 570,184 shares ($2.0M) at $3.56 avg across 6 transactions

BROADWOOD PARTNERS, L.P., a 10% owner, executed 6 separate purchases totaling 570,184 shares for $2,032,251.44 between April 16–27, 2026, at a blended average price of $3.56. The current price of $3.84 is 54.7% below the 52-week high of $8.48, and the stock is down 44.3% over the past 90 days, though up 7.9% over the past 30 days. The company is unprofitable (full-year net income was negative $10,854,000.00 with latest-quarter revenue of $260,000.00) but showed annual revenue growth of +115.6%. Broadwood's cross-ticker track record shows a 0.00% win rate at the 90-day mark with average returns of -14.9%, and its prior 5 trades at IMDX remain outcome-unmeasurable. The scale of this capital commitment—$2.0M added to an already substantial 12.68M-share position—alongside accumulation across depressed price levels and a period of recent gains (30-day +7.9%) follows multiple purchases by the same filer within days, warranting close monitoring of whether this reflects changed conviction about company fundamentals or portfolio allocation.

Broadwood Partners (10% owner) purchased 182,861 shares across 3 dates for $652,875.63; stock now -53.0% from 52-week high

Broadwood Partners executed 3 separate purchases totaling 182,861 shares between April 16–20, 2026 at a blended average price of $3.57, adding 1.5% to its existing 11.93M share position. The timing is concerning: the stock is currently trading at $3.99, down 53.0% from its 52-week high of $8.48 and down 6.3% over the past 30 days. Across the insider's cross-ticker track record, prior buys show an average 90-day return of -18.2% with a 0.00% win rate, and at IMDX specifically, the two prior buys in February 2026 posted 30-day returns of -15.0% and -34.0%. The company itself faces fundamental headwinds: while annual revenue grew 115.6%, the most recent quarter generated only $260,000 in revenue against a $-10.9M net loss, and the company was unprofitable over its most recent full fiscal year. The purchase does not reverse the negative momentum or address the underlying profitability challenges.

Broadwood Partners bought 670,213 shares in 3 tranches for $12.3M (avg $18.30) as stock down 34.1% from 52-week high.

Broadwood Partners, a director of STAAR Surgical, executed three separate purchases totaling 670,213 shares for $12,266,545.29 between March 11–13, 2026, at an average price of $18.30—well below the 52-week high of $28.57 but only 0.2% below the current price of $18.84. The company's fundamentals are distressed: annual revenue declined 23.7% year-over-year, the most recent full fiscal year was unprofitable, and the stock has fallen 21.9% over the past 90 days. Broadwood's prior trades at STAA—five buys in early January 2026—all posted negative 30-day returns (ranging from -19.9% to -21.9%), and none of the insider's broader cross-ticker buy history (20 prior buys with a 25% win rate at 90 days) demonstrated successful timing. This fresh accumulation in a deteriorating business environment, combined with a poor track record of buy timing at this specific ticker, suggests material risk rather than a conviction-driven inflection signal.

IMDX: Broadwood Partners acquires 521,739 shares for $2,999,999.25; stock down 34.2% from 52-week high despite 25.2% revenue growth.

Broadwood Partners, a 10% owner, purchased 521,739 shares at $5.75 on 2026-02-10 for $2,999,999.25, expanding holdings to 11,931,839 shares (+4.6% increase). The acquisition occurs against a backdrop of significant recent price weakness: the stock is -34.2% from its 52-week high of $8.48 and has declined -22.8% over the past 30 days. Simultaneously, the company reported 25.2% annual revenue growth, yet remains unprofitable with a net loss of $10,854,000.00 in its most recent full fiscal year and minimal quarterly revenue of $260,000.00. The cross-ticker track record shows this insider's prior 20 open-market buys yielded an average 90-day return of +10.4% with a 100.00% win rate, though zero measurable same-ticker outcomes exist. The open-market purchase at a price 3.0% above the current market price of $5.58 occurs during a steep drawdown, creating a key interpretive tension: whether the large position increase reflects conviction in the underlying business fundamentals or is simply a function of the insider's portfolio allocation discipline at price levels significantly above recent market levels.

BROADWOOD PARTNERS (10% owner) buys 27,485 shares at $22.05; 5 buys in 3 days amid -26.0% drop from 52-week high.

BROADWOOD PARTNERS, a 10% owner of STAAR SURGICAL, executed 2 separate purchases totaling 27,485 shares for $606,137.70 on 2026-01-09, at an average price of $22.05 per share. This transaction is part of a concentrated buying pattern—the filer has made 5 purchases at this ticker over a 3-day window (2026-01-06 through 2026-01-09), adding 27,485 shares to holdings of 15.45M shares. The timing occurs against a backdrop of significant stock decline: the current price of $21.13 is -26.0% from the 52-week high of $28.57 and down -12.4% over the past 30 days. The company's fundamentals show quarterly revenue of $94.7M with net income of $8.9M, but full-year profitability was negative (full-year net income was negative), and annual revenue growth contracted -2.6% year-over-year. Across BROADWOOD's cross-ticker open-market trading history, the filer has recorded a 100.00% 90-day win rate on 20 prior buys with average 90-day returns of +10.1%, though measurable outcomes are not yet available for any of the 5 same-ticker trades at STAA.

Broadwood Partners accumulates 406,653 STAA shares across 4 days for $8.8M as stock declines 11.4% in 30 days.

Broadwood Partners, a 10% shareholder, executed 8 separate purchases totaling 406,653 shares (406.7K shares) over 4 days (January 6–8, 2026) at prices ranging from $21.01 to $22.38, spending $8,817,663.73. The blended average purchase price of $21.68 sits above the current price of $22.50 and reflects buying activity during a 30-day decline of -11.4%. At STAA specifically, the insider's 5 prior buys over the preceding week (November 19–21) have returned -5.0% to -10.2% at the 30-day mark, with measurable 90-day outcomes still pending. The company reported negative full-year net income despite quarterly revenue of $94,732,000.00 ($94.7M) and faces annual revenue contraction of -2.6%. The multi-transaction structure and large capital deployment ($8.8M) during a period of weakening stock price and negative fundamentals merit attention to understand the buyer's assessment of valuation and near-term prospects.

Broadwood Partners purchases 1,500,000 shares for $41.1M at STAA; 10% holder adds 11.1% to holdings over 3 days

Broadwood Partners, a 10% shareholder, executed three separate open-market purchases totaling 1,500,000 (1.50M shares) over November 19–21 at a blended average price of $27.37, increasing holdings from 13,519,491 to 15,019,491 shares (+11.1%). The transaction size ($41,060,317.10) represents a material capital commitment, executed across three tranches at progressively higher prices ($26.42, $27.14, and $27.86). Notably, this insider's prior five trades at STAA were all well-timed, with all 5 of 5 prior buys producing positive 90-day returns (ranging from +6.6% to +12.9%). The current stock price of $28.00 sits 3.8% below the 52-week high of $29.10 but 12.4% above the 30-day average, and the company reported revenue of $94,732,000 and net income of $8,884,000 in the latest quarter, though full-year net income was negative. The sequential price escalation during the purchase window and the consistent pattern of prior well-timed buys at this ticker merit investor attention.